metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHNSCC - L2 - all population metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - all population
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-040 (all population), 2018 Lancet 2019; 393:156-167 BMJ Open 2020 Dec 18;10(12):e038867. J Immunother Cancer 2019 Apr 3;7(1):96. Mod Pathol 2020 Nov 25. NCT02252042	RCT	mHNSCC - L2 - all population	pembrolizumab	chemotherapy (methotrexate, docetaxel or cetuximab)	patients with recurrent or metastatic head and neck squamous cell cancer that progressed during or after platinum-containing treatment : all population	247 / 248	some concern	conclusif	demonstrated 20 % decrease in deaths (OS) (PE)
mHNSCC - L2 - PDL1 positive metastatic-recurrent HNSCC (mHNSCC) mHNSCC - 2nd line (L2) mHNSCC - L2 - PDL1 positive
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-040 (CPS >1), 2018 Lancet 2019; 393:156-167 BMJ Open 2020 Dec 18;10(12):e038867. J Immunother Cancer 2019 Apr 3;7(1):96. Mod Pathol 2020 Nov 25. NCT02252042	RCT	mHNSCC - L2 - PDL1 positive	pembrolizumab	chemotherapy (methotrexate, docetaxel or cetuximab)	patients with recurrent or metastatic head and neck squamous cell cancer that progressed during or after platinum-containing treatment : only patients with CPS > 1	196 / 191	some concern	conclusif	demonstrated 26 % decrease in deaths (OS) (PE)